CoChat

Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans

Open access
Lerche, Susanne, Brock, Birgitte, Rungby, Jørgen, Bøtker, Hans E., Møller, Niels, Rodell, Anders, Bibby, Bo Martin, Holst, Jens J., Schmitz, Ole, Gjedde, Albert · 2008 · Diabetes
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE— Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS— We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary-pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS— On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter (P = 0.05) and by 25–30% in individual gray matter regions (P = 0.02–0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS— We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fluctuation when plasma glucose is increased.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db07-1162

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 52

Metadata

Authors
Lerche, S., Brock, B., Rungby, J., Bøtker, H. E., Møller, N., Rodell, A., Bibby, B. M., Holst, J. J., Schmitz, O., & Gjedde, A.
Venue
Diabetes
Published
2008-02-01
Volume
57
Issue
2
Pages
325-331
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2135856860
Cited by
52
References
10
FWCI
1.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. https://app.cochat.ai/papers/10.2337/db07-1162
The paper
Lerche, S., Brock, B., Rungby, J., Bøtker, H. E., Møller, N., Rodell, A., Bibby, B. M., Holst, J. J., Schmitz, O., & Gjedde, A. (2008). Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. Diabetes. https://doi.org/10.2337/db07-1162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.